Advances in understanding the molecular basis of frontotemporal dementia

Nature Reviews Neurology

Volumn 8, Issue 8, 2012, Pages 423-434

  Rademakers, Rosa ^a   Neumann, Manuela ^b   MacKenzie, Ian R ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FUSED IN SARCOMA PROTEIN; NUCLEIC ACID BINDING PROTEIN; PROGRANULIN; PROTEIN FET; SORTILIN; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; BIOACCUMULATION; CHROMOSOME 9 OPEN READING FRAME 72 GENE; CYTOLOGY; DNA MODIFICATION; FRONTOTEMPORAL DEMENTIA; FUSED IN SARCOMA GENE; GAIN OF FUNCTION MUTATION; GENE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC PARAMETERS; GENETIC RISK; GENETIC VARIABILITY; HUMAN; LOSS OF FUNCTION MUTATION; MOLECULAR PATHOLOGY; MUTATION RATE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGRANULIN GENE; PROTEIN FUNCTION; REPEAT SIZE; REVIEW; TAR DNA BINDING PROTEIN 43 GENE; TDP 43 PROTEINOPATHY; TRANSMEMBRANE PROTEIN 106B GENE;

AMYOTROPHIC LATERAL SCLEROSIS; DNA-BINDING PROTEINS; FRONTOTEMPORAL DEMENTIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PROTEINS; TAU PROTEINS;

EID: 84864981763     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.117     Document Type: Review

References (159)

1. Bird, T. et al. Epidemiology and genetics of frontotemporal dementia/Pick's disease. Ann. Neurol. 54 (Suppl. 5), S29-S31 (2003).
2. Feldman, H. et al. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): Study methods and baseline results. Neuroepidemiology 22, 265-274 (2003).
3. [No authors listed] Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J. Neurol. Neurosurg. Psychiatry 57, 416-418 (1994).
4. McKhann, G. M. et al. Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch. Neurol. 58, 1803-1809 (2001).
5. Neary, D. et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51, 1546-1554 (1998).
6. Burrell, J. R., Kiernan, M. C., Vucic, S. & Hodges, J. R. Motor neuron dysfunction in frontotemporal dementia. Brain 134, 2582-2594 (2011).
7. Lomen-Hoerth, C., Anderson, T. & Miller, B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 59, 1077-1079 (2002).
8. Rohrer, J. D. et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 73, 1451-1456 (2009).
9. Seelaar, H. et al. Distinct genetic forms of frontotemporal dementia. Neurology 71, 1220-1226 (2008).
10. Hutton, M. et al. Association of missense and 5' splice site mutations in tau with the inherited dementia FTDP 17. Nature 393, 702-705 (1998).
11. Poorkaj, P. et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815-825 (1998).
12. Spillantini, M. G. et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl Acad. Sci. USA 95, 7737-7741 (1998).
13. Alzheimer Disease & Frontotemporal Dementia Mutation Database [online], http://www.molgen.ua.ac.be/ftdmutations (2012).
14. Rademakers, R., Cruts, M. & Van Broeckhoven, C. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum. Mutat. 24, 277-295 (2004).
15. Baker, M. et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916-919 (2006).
16. Cruts, M. et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920-924 (2006).
17. Watts, G. D. et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36, 377-381 (2004).
18. Skibinski, G. et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 37, 806-808 (2005).
19. Boxer, A. L. et al. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J. Neurol. Neurosurg. Psychiatr. 82, 196-203 (2011).
20. Gijselinck, I. et al. Identification of 2 loci at chromosomes 9 and 14 in a multiplex family with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch. Neurol. 67, 606-616 (2010).
21. Le Ber, I. et al. Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology 72, 1669-1676 (2009).
22. Luty, A. A. et al. Pedigree with frontotemporal lobar degeneration-motor neuron disease and Tar DNA binding protein 43 positive neuropathology: Genetic linkage to chromosome 9. BMC Neurol. 8, 32 (2008).
23. Momeni, P. et al. Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol. 6, 44 (2006).
24. Morita, M. et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 66, 839-844 (2006).
25. Pearson, J. P. et al. Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosome 9p. J. Neurol. 258, 647-655 (2011).
26. Valdmanis, P. N. et al. Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. Arch. Neurol. 64, 240-245 (2007).
27. Vance, C. et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 129, 868-876 (2006).
28. DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-256 (2011).
29. Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257-268 (2011).
30. Cairns, N. J. et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 114, 5-22 (2007).
31. Mackenzie, I. R. et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: Consensus recommendations. Acta Neuropathol. 117, 15-18 (2009).
32. Mackenzie, I. R. et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: An update. Acta Neuropathol. 119, 1-4 (2010).
33. Lipton, A. M., White, C. L. 3rd & Bigio, E. H. Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol. 108, 379-385 (2004).
34. Mackenzie, I. R. et al. Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathol. 112, 551-559 (2006).
35. Arai, T. et al. TDP 43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602-611 (2006).
36. Neumann, M. et al. Ubiquitinated TDP 43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133 (2006).
37. Kwiatkowski, T. J. Jr et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205-1208 (2009).
38. Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211 (2009).
39. Munoz, D. G. et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol. 118, 617-627 (2009).
40. Neumann, M. et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132, 2922-2931 (2009).
41. Neumann, M. et al. Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol. 118, 605-616 (2009).
42. Neumann, M. et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134, 2595-2609 (2011).
43. Gijselinck, I., Van Broeckhoven, C. & Cruts, M. Granulin mutations associated with frontotemporal lobar degeneration and related disorders: An update. Hum. Mutat. 29, 1373-1386 (2008).
44. Bateman, A. & Bennett, H. P. The granulin gene family: From cancer to dementia. Bioessays 31, 1245-1254 (2009).
45. Finch, N. et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132, 583-591 (2009).
46. Ghidoni, R., Benussi, L., Glionna, M., Franzoni, M. & Binetti, G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71, 1235-1239 (2008).
47. Sleegers, K. et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann. Neurol. 65, 603-609 (2009).
48. Beck, J. et al. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain 131, 706-720 (2008).
49. Gass, J. et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum. Mol. Genet. 15, 2988-3001 (2006).
50. Le Ber, I. et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Human. Mut. 28, 846-855 (2007).
51. Moreno, F. et al. Frontotemporoparietal dementia: Clinical phenotype associated with the c.709-1GA PGRN mutation. Neurology 73, 1367-1374 (2009).
52. Snowden, J. S. et al. Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain 129, 3091-3102 (2006).
53. Masellis, M. et al. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain 129, 3115-3123 (2006).
54. Cruts, M. & Van Broeckhoven, C. Loss of progranulin function in frontotemporal lobar degeneration. Trends Genet. 24, 186-194 (2008).
55. Van Deerlin, V. M. et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP 43 inclusions. Nat. Genet. 42, 234-239 (2010).
56. Cruchaga, C. et al. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch. Neurol. 68, 581-586 (2011).
57. Finch, N. et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 76, 467-474 (2011).
58. Van Der Zee, J. et al. TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 134, 808-815 (2011).
59. Jiao, J., Herl, L. D., Farese, R. V. & Gao, F. B. MicroRNA 29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. PLoS ONE 5, e10551 (2010).
60. Wang, W. X. et al. miR 107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. Am. J. Pathol. 177, 334-345 (2010).
61. Rademakers, R. et al. Common variation in the miR 659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum. Mol. Genet. 17, 3631-3642 (2008).
62. Brouwers, N. et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 71, 656-664 (2008).
63. Lee, M. J., Chen, T. F., Cheng, T. W. & Chiu, M. J. rs5848 variant of progranulin gene is a risk of Alzheimer's disease in the Taiwanese population. Neurodegener. Dis. 8, 216-220 (2011).
64. Viswanathan, J. et al. An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 150B, 747-750 (2009).
65. Cenik, B. et al. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: Rational therapeutic approach to frontotemporal dementia. J. Biol. Chem. 286, 16101-16108 (2011).
66. Capell, A. et al. Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J. Neurosci. 31, 1885-1894 (2011).
67. Gao, X. et al. Progranulin promotes neurite outgrowth and neuronal differentiation by regulating GSK-3β. Protein Cell 1, 552-562 (2010).
68. Ryan, C. L. et al. Progranulin is expressed within motor neurons and promotes neuronal cell survival. BMC Neurosci. 10, 130 (2009).
69. Tapia, L. et al. Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses. J. Neurosci. 31, 11126-11132 (2011).
70. Van Damme, P. et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J. Cell. Biol. 181, 37-41 (2008).
71. Kleinberger, G. et al. Increased caspase activation and decreased TDP 43 solubility in progranulin knockout cortical cultures. J. Neurochem. 115, 735-747 (2010).
72. Nedachi, T., Kawai, T., Matsuwaki, T., Yamanouchi, K. & Nishihara, M. Progranulin enhances neural progenitor cell proliferation through glycogen synthase kinase 3β phosphorylation. Neuroscience 185, 106-115 (2011).
73. Rosen, E. Y. et al. Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. Neuron 71, 1030-1042 (2011).
74. Xu, J. et al. Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling. Neurobiol. Aging 32, 2326.e5-2326.e16 (2011).
75. Guo, A., Tapia, L., Bamji, S. X., Cynader, M. S. & Jia, W. Progranulin deficiency leads to enhanced cell vulnerability and TDP 43 translocation in primary neuronal cultures. Brain Res. 1366, 1-8 (2010).
76. Carrasquillo, M. M. et al. Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma. Am. J. Hum. Genet. 87, 890-897 (2010).
77. Hu, F. et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68, 654-667 (2010).
78. Tang, W. et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332, 478-484 (2011).
79. Boeve, B. F. et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 135, 765-783 (2012).
80. Brettschneider, J. et al. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol. 123, 825-839 (2012).
81. Byrne, S. et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: A population-based cohort study. Lancet Neurol. 11, 232-240 (2012).
82. Chio, A. et al. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain 135, 784-793 (2012).
83. Cooper-Knock, J. et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 135, 751-764 (2012).
84. Floris, G. et al. Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: A peculiar phenotype? J. Neurol. http://dx.doi.org/10. 1007/s00415-012-6444-3.
85. Gijselinck, I. et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: A gene identification study. Lancet Neurol. 11, 54-65 (2012).
86. Hsiung, G. Y. et al. Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain 135, 709-722 (2012).
87. Kandiah, N. et al. Case report of an Asian patient with FTD-ALS due to C9ORF72 mutation. Can. J. Neurol. Sci. (in press).
88. Mahoney, C. J. et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features. Brain 135, 736-750 (2012).
89. Majounie, E. et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study. Lancet Neurol. 11, 323-330 (2012).
90. Mok, K. Y. et al. High frequency of the expanded C9ORF72 hexanucleotide repeat in familial and sporadic Greek ALS patients. Neurobiol. Aging http://dx.doi.org/10.1016/j.neurobiolaging.2012.02.021.
91. Murray, M. E. et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 122, 673-690 (2011).
92. Sabatelli, M. et al. C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiol. Aging http://dx.doi.org/10.1016/j. neurobiolaging.2012.02.011.
93. Simon-Sanchez, J. et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain 135, 723-735 (2012).
94. Snowden, J. S. et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 135, 693-708 (2012).
95. Stewart, H. et al. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol. 123, 409-417 (2012).
96. Mok, K. et al. Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol. Aging 33, 209.e3-209.e8 (2012).
97. Rademakers, R. C9orf72 repeat expansions in patients with ALS and FTD. Lancet Neurol. 11, 297-298 (2012).
98. Whitwell, J. L. et al. Neuroimaging signatures of frontotemporal dementia genetics: c9orf72, tau, progranulin and sporadics. Brain 135, 794-806 (2012).
99. Al-Sarraj, S. et al. p62 positive, TDP 43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol. 122, 691-702 (2011).
100. Troakes, C. et al. An MND/ALS phenotype associated with C9orf72 repeat expansion: Abundant p62-positive, TDP 43 negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline. Neuropathology http://dx.doi.org/10.1111/j.1440-1789.2011.01286.x.
101. Lavedan, C. et al. Myotonic dystrophy: Size- and sex-dependent dynamics of CTG meiotic instability, and somatic mosaicism. Am. J. Hum. Genet. 52, 875-883 (1993).
102. Matsuura, T. et al. Somatic and germline instability of the ATTCT repeat in spinocerebellar ataxia type 10. Am. J. Hum. Genet. 74, 1216-1224 (2004).
103. Moseley, M. L. et al. SCA8 CTG repeat: En masse contractions in sperm and intergenerational sequence changes may play a role in reduced penetrance. Hum. Mol. Genet. 9, 2125-2130 (2000).
104. Renoux, A. J. & Todd, P. K. Neurodegeneration the RNA way. Prog. Neurobiol. 97, 173-189 (2011).
105. Rademakers, R. et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat. Genet. 44, 200-205 (2012).
106. Kabashi, E. et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP 43) cause motor deficits in vivo. Hum. Mol. Genet. 19, 671-683 (2010).
107. Sreedharan, J. et al. TDP 43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668-1672 (2008).
108. Deng, H. X. et al. Mutations in UBQLN2 cause dominant X linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211-215 (2011).
109. Buratti, E. & Baralle, F. E. The multiple roles of TDP 43 in pre-mRNA processing and gene expression regulation. RNA Biol. 7, 420-429 (2010).
110. Polymenidou, M. et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP 43. Nat. Neurosci. 14, 459-468 (2011).
111. Tollervey, J. R. et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP 43. Nat. Neurosci. 14, 452-458 (2011).
112. Van Deerlin, V. M. et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP 43 neuropathology: A genetic and histopathological analysis. Lancet Neurol. 7, 409-416 (2008).
113. Kovacs, G. G. et al. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov. Disord. 24, 1843-1847 (2009).
114. Neumann, M. et al. TDP 43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J. Neuropathol. Exp. Neurol. 66, 152-157 (2007).
115. Cairns, N. J. et al. TDP 43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol. 171, 227-240 (2007).
116. Mackenzie, I. R. et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: Classification and relation to clinical phenotype. Acta Neuropathol. 112, 539-549 (2006).
117. Mackenzie, I. R. et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 122, 111-113 (2011).
118. Sampathu, D. M. et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am. J. Pathol. 169, 1343-1352 (2006).
119. Hasegawa, M. et al. Molecular dissection of TDP 43 proteinopathies. J. Mol. Neurosci. 45, 480-485 (2011).
120. Lee, E. B., Lee, V. M. & Trojanowski, J. Q. Gains or losses: Molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 13, 38-50 (2012).
121. Mackenzie, I. R., Rademakers, R. & Neumann, M. TDP 43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 9, 995-1007 (2010).
122. Da Cruz, S. & Cleveland, D. W. Understanding the role of TDP 43 and FUS/TLS in ALS and beyond. Curr. Opin. Neurobiol. 21, 904-919 (2011).
123. Tan, A. Y. & Manley, J. L. The TET family of proteins: Functions and roles in disease. J. Mol. Cell Biol. 1, 82-92 (2009).
124. Hoell, J. I. et al. RNA targets of wild-type and mutant FET family proteins. Nat. Struct. Mol. Biol. 18, 1428-1431 (2011).
125. Urwin, H. et al. FUS pathology defines the majority of tau- and TDP 43 negative frontotemporal lobar degeneration. Acta Neuropathol. 120, 33-41 (2010).
126. Mackenzie, I. R. et al. Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: Two distinct patterns correlating with disease severity and mutation. Acta Neuropathol. 122, 87-98 (2011).
127. Mackenzie, I. R. et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol. 121, 207-218 (2011).
128. Couthouis, J. et al. A yeast functional screen predicts new candidate ALS disease genes. Proc. Natl Acad. Sci. USA 108, 20881-20890 (2011).
129. Couthouis, J. et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum. Mol. Genet. http://dx.doi.org/10. 1093/hmg/dds116.
130. Ticozzi, N. et al. Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 156, 285-290 (2011).
131. Dormann, D. et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 29, 2841-2857 (2010).
132. Ito, D., Seki, M., Tsunoda, Y., Uchiyama, H. & Suzuki, N. Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. Ann. Neurol. 69, 152-162 (2010).
133. Belyanskaya, L. L., Delattre, O. & Gehring, H. Expression and subcellular localization of Ewing sarcoma (EWS) protein is affected by the methylation process. Exp. Cell Res. 288, 374-381 (2003).
134. Jobert, L., Argentini, M. & Tora, L. PRMT1 mediated methylation of TAF15 is required for its positive gene regulatory function. Exp. Cell Res. 315, 1273-1286 (2009).
135. Rappsilber, J., Friesen, W. J., Paushkin, S., Dreyfuss, G. & Mann, M. Detection of arginine dimethylated peptides by parallel precursor ion scanning mass spectrometry in positive ion mode. Anal. Chem. 75, 3107-3114 (2003).
136. Fronz, K. et al. Arginine methylation of the nuclear poly(A) binding protein weakens the interaction with its nuclear import receptor, transportin. J. Biol. Chem. 286, 32986-32994 (2011).
137. Deloulme, J. C., Prichard, L., Delattre, O. & Storm, D. R. The prooncoprotein EWS binds calmodulin and is phosphorylated by proteinkinase C through an IQ domain. J. Biol. Chem. 272, 27369-27377 (1997).
138. Perrotti, D. et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J. 17, 4442-4455 (1998).
139. Leemann-Zakaryan, R. P., Pahlich, S., Grossenbacher, D. & Gehring, H. Tyrosine phosphorylation in the C terminal nuclear localization and retention signal (C-NLS) of the EWS protein. Sarcoma 2011, 218483 (2011).
140. Page, T. et al. FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: A frontotemporal lobar degeneration with FUS proteinopathy. J. Mol. Neurosci. 45, 409-421 (2011).
141. Lanson, N. A. Jr & Pandey, U. B. FUS-related proteinopathies: Lessons from animal models. Brain Res. http://dx.doi.org/10.1016/j.brainres.2012.01. 039.
142. Josephs, K. A. et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 122, 137-153 (2011).
143. Rohrer, J. D. & Warren, J. D. Phenotypic signatures of genetic frontotemporal dementia. Curr. Opin. Neurol. 24, 542-549 (2011).
144. Hu, W. T., Trojanowski, J. Q. & Shaw, L. M. Biomarkers in frontotemporal lobar degenerations-progress and challenges. Prog. Neurobiol. 95, 636-648 (2011).
145. Noto, Y. et al. Elevated CSF TDP 43 levels in amyotrophic lateral sclerosis: Specificity, sensitivity, and a possible prognostic value. Amyotroph. Lateral Scler. 12, 140-143 (2011).
146. Time is ripe for clinical trials in frontotemporal degeneration. Alzheimer Research Forum [online], http://www.alzforum.org/new/pdf/FTLDSeries. pdf (2011).
147. Pick, A. Über die Beziehungen Der senilen Hirnatrophie zur Aphasie [German]. Prager medicinische Wochenschrift 17, 165-167 (1892).
148. Alzheimer, A. Über eigenartige Krankheitsfäelle des späeteren Alters [German]. Z. Gesamte Neurol. Psychiatrie 4, 356-385 (1911).
149. Rebeiz, J. J., Kolodny, E. H. & Richardson, E. P. Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch. Neurol. 18, 20-33 (1968).
150. Steele, J. C., Richardson, J. C. & Olszewski, J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch. Neurol. 10, 333-359 (1964).
151. Constantinidis, J., Richard, J. & Tissot, R. Pick's disease. Histological and clinical correlations. Eur. Neurol. 11, 208-217 (1974).
152. Lee, V. M., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159 (2001).
153. Knopman, D. S., Mastri, A. R., Frey, W. H. 2nd, Sung, J. H. & Rustan, T. Dementia lacking distinctive histologic features: A common non-Alzheimer degenerative dementia. Neurology 40, 251-256 (1990).
154. Jackson, M., Lennox, G. & Lowe, J. Motor neurone disease-inclusion dementia. Neurodegeneration 5, 339-350 (1996).
155. Mackenzie, I. R., Foti, D., Woulfe, J. & Hurwitz, T. A. Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP 43 negative neuronal inclusions. Brain 131, 1282-1293 (2008).
156. Roeber, S., Mackenzie, I. R., Kretzschmar, H. A. & Neumann, M. TDP 43 negative FTLD U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol. 116, 147-157 (2008).
157. Laaksovirta, H. et al. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: A genome-wide association study. Lancet Neurol. 9, 978-985 (2010).
158. Shatunov, A. et al. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: A genome-wide association study. Lancet Neurol. 9, 986-994 (2010).
159. Van Es, M. A. et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat. Genet. 41, 1083-1087 (2009).